Evogene Ltd (NASDAQ:EVGN) saw a large drop in short interest in September. As of September 30th, there was short interest totalling 10,600 shares, a drop of 36.1% from the August 30th total of 16,600 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 8,800 shares, the short-interest ratio is presently 1.2 days.
Shares of NASDAQ EVGN traded up $0.05 during midday trading on Friday, hitting $1.64. 2,000 shares of the company’s stock were exchanged, compared to its average volume of 1,979. The company has a debt-to-equity ratio of 0.06, a current ratio of 10.14 and a quick ratio of 10.14. Evogene has a twelve month low of $1.34 and a twelve month high of $3.01. The firm’s fifty day simple moving average is $1.63 and its 200-day simple moving average is $1.71.
Evogene (NASDAQ:EVGN) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.35). Evogene had a negative return on equity of 37.62% and a negative net margin of 1,193.65%. The business had revenue of $0.19 million for the quarter.
Separately, ValuEngine raised Evogene from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
An institutional investor recently bought a new position in Evogene stock. Eidelman Virant Capital bought a new position in shares of Evogene Ltd (NASDAQ:EVGN) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 63,600 shares of the biotechnology company’s stock, valued at approximately $102,000. Eidelman Virant Capital owned approximately 0.25% of Evogene as of its most recent filing with the SEC. Institutional investors own 29.23% of the company’s stock.
Evogene Company Profile
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.
Featured Story: Margin
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.